TeraRecon Launches AI-Powered Neuro Suite
The artificial intelligence (AI)-powered Neuro Suite reportedly enables radiologists to access leading neurological AI algorithm solutions in the field, including the brain magnetic resonance imaging (MRI) segmentation capabilities of the Combinostics’ algorithm that can help differentiate degenerative pathologies such as Alzheimer’s disease and dementia.
Emphasizing timely neurological disease triage and access to “a first-in-class capability and the only open (artificial intelligence) AI architecture” for clinical AI, ConcertAI’s TeraRecon has launched Neuro Suite.
The Neuro Suite platform allows radiologists to access a variety of AI-powered neuroimaging modalities from leading vendors in the neurology field, including Combinostics, Imaging Biometrics and Cercare Medical, according to TeraRecon.
For the diagnosis of degenerative cerebral pathologies including Alzheimer’s disease and dementia, the Combinostics algorithm offers high-quality segmentation of brain magnetic resonance imaging (MRI) to help assess atrophy. TeraRecon said the algorithm from Imaging Biometrics provides radiologists with insights into the blood supply and oxygenation of brain tumors. Access to the proprietary perfusion technology of Cercare Medical enables neurovascular function assessment down to the capillary level, according to TeraRecon.
“We are proud to enhance our neurological offerings beyond TR Neuro to an entire Neuro Suite, extending to our clinician customers an amazing array of tools streamlined into one place and able to be interacted with to help identify and treat critical neurological issues,” said Dan McSweeney, the president of TeraRecon.
(Editor’s note: For related content, see “TeraRecon Launches AI-Driven Neuroimaging Platform” and “FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting.”)
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
